Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington , D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): February 25, 2017

 

PixarBio Corporation

(Name of Small Business Issuer in its Charter)

 

Delaware		47-1945113
(State or Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

 

200 Boston Avenue, Suite 1875

Medford , MA 02155

(Address of principal executive offices)

 

[phone]

(Telephone Number of Principal Executive Offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 8.01 Other Events.

 

On February 25, 2017, PixarBio Corp. (the "Company") posted a PowerPoint presentation on its website entitled “14-Day NeuroRelease Post-Surgical Pain Treatment Pre-Clinical Progress”. The PowerPoint presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

ITEM 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit No.		Description
99.1		Pre-clinical Data Presentation dated February 25, 2017– 14-Day NeuroRelease Post-Surgical Pain Treatment Pre-Clinical Progress

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	PixarBio Corporation (the Company)
Dated: February 28, 2017	By:	/s/ Francis M. Reynolds
		Francis M. Reynolds
	Title:	Chief Executive Officer

  

3